| scholarly article | Q13442814 |
| P356 | DOI | 10.1200/JCO.2013.54.5384 |
| P698 | PubMed publication ID | 25332247 |
| P50 | author | Seock-Ah Im | Q58821370 |
| Sandra M. Swain | Q37839297 | ||
| Javier Cortes | Q43114235 | ||
| P2093 | author name string | José Baselga | |
| Graham Ross | |||
| Emma Clark | |||
| Astrid Kiermaier | |||
| P433 | issue | 33 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | placebo | Q269829 |
| biomarker | Q864574 | ||
| P304 | page(s) | 3753-3761 | |
| P577 | publication date | 2014-10-20 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer. | |
| P478 | volume | 32 |
| Q47158524 | A comprehensive review of heregulins, HER3, and HER4 as potential therapeutic targets in cancer |
| Q38644521 | A review of HER2-targeted therapy in breast and ovarian cancer: lessons from antiquity - CLEOPATRA and PENELOPE. |
| Q53175758 | A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients. |
| Q37099507 | A whole-genome sequence and transcriptome perspective on HER2-positive breast cancers |
| Q26830671 | Activation of the PI3K/mTOR/AKT pathway and survival in solid tumors: systematic review and meta-analysis |
| Q27853332 | Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial |
| Q38646686 | Afatinib-based combination regimens for the treatment of solid tumors: rationale, emerging strategies and recent progress |
| Q41564734 | Amphiregulin confers trastuzumab resistance via AKT and ERK activation in HER2-positive breast cancer |
| Q35793821 | Amphiregulin enhances alpha6beta1 integrin expression and cell motility in human chondrosarcoma cells through Ras/Raf/MEK/ERK/AP-1 pathway. |
| Q47615981 | An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression. |
| Q50040088 | An update on first line therapies for metastatic breast cancer |
| Q26797471 | Analysis of different HER-2 mutations in breast cancer progression and drug resistance |
| Q89907802 | Analysis of the Cost-Effectiveness of Liquid Biopsy to Determine Treatment Change in Patients with Her2-Positive Advanced Breast Cancer in Colombia |
| Q36879470 | Anti-tumor efficacy of BEZ235 is complemented by its anti-angiogenic effects via downregulation of PI3K-mTOR-HIF1alpha signaling in HER2-defined breast cancers |
| Q47851750 | Antibody-Drug Conjugates for the Treatment of Solid Tumors: Clinical Experience and Latest Developments |
| Q34296114 | Association of phosphatase and tensin homolog low and phosphatidylinositol 3-kinase catalytic subunit alpha gene mutations on outcome in human epidermal growth factor receptor 2-positive metastatic breast cancer patients treated with first-line lapa |
| Q38694128 | BRAF, KRAS and PIK3CA Mutation and Sensitivity to Trastuzumab in Breast Cancer Cell Line Model |
| Q37221249 | Benefit to neoadjuvant anti-human epidermal growth factor receptor 2 (HER2)-targeted therapies in HER2-positive primary breast cancer is independent of phosphatase and tensin homolog deleted from chromosome 10 (PTEN) status |
| Q92520871 | BioPATH: A Biomarker Study in Asian Patients with HER2+ Advanced Breast Cancer Treated with Lapatinib and Other Anti-HER2 Therapy |
| Q37633741 | Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer |
| Q38778536 | Biomarkers for Predicting Response to Anti-HER2 Agents |
| Q88716138 | Breast cancer: T-DM1 - an important agent in the history of breast cancer management |
| Q34461019 | Buparlisib , an oral pan-PI3K inhibitor for the treatment of breast cancer |
| Q52595390 | Characterization of PIK3CA and PIK3R1 somatic mutations in Chinese breast cancer patients. |
| Q49821380 | Circulating tumor DNA as a novel tool to shape clinical trial designs with the potential to impact outcomes: a focus on PI3K inhibitors |
| Q36575502 | Clinical Implications of Mutations in the PI3K Pathway in HER2+ Breast Cancer: Prognostic or Predictive? |
| Q37718221 | Clinical outcomes based on multigene profiling in metastatic breast cancer patients |
| Q57106943 | Clinico-pathological Features of Mutation in HER2-Positive Breast Cancer of Indian Population |
| Q58112887 | Clinicopathological and prognostic correlations of HER3 expression and its degradation regulators, NEDD4-1 and NRDP1, in primary breast cancer |
| Q35846874 | Comparison of targeted next-generation sequencing and Sanger sequencing for the detection of PIK3CA mutations in breast cancer |
| Q38563592 | De novo resistance biomarkers to anti-HER2 therapies in HER2-positive breast cancer. |
| Q39421814 | De-escalation of treatment in HER2-positive breast cancer: Determinants of response and mechanisms of resistance |
| Q38888022 | Deciphering and Targeting Oncogenic Mutations and Pathways in Breast Cancer |
| Q47103332 | Development and clinical application of anti-HER2 monoclonal and bispecific antibodies for cancer treatment |
| Q37690005 | Direct inhibition of PI3K in combination with dual HER2 inhibitors is required for optimal antitumor activity in HER2+ breast cancer cells |
| Q92143276 | Efficacy of PI3K inhibitors in advanced breast cancer |
| Q41058774 | ErbB activation signatures as potential biomarkers for anti-ErbB3 treatment in HNSCC. |
| Q28084565 | ErbB polymorphisms: insights and implications for response to targeted cancer therapeutics |
| Q34485373 | Evaluating the predictive value of biomarkers for efficacy outcomes in response to pertuzumab- and trastuzumab-based therapy: an exploratory analysis of the TRYPHAENA study |
| Q26783895 | Evaluation of antiangiogenic efficacy in advanced hepatocellular carcinoma: Biomarkers and functional imaging |
| Q38843575 | Extracellular Matrix/Integrin Signaling Promotes Resistance to Combined Inhibition of HER2 and PI3K in HER2+ Breast Cancer |
| Q52560262 | Genomic Profiling of HER2-Positive Gastric Cancer: PI3K/Akt/mTOR Pathway as Predictor of Outcomes in HER2-Positive Advanced Gastric Cancer Treated with Trastuzumab. |
| Q50115014 | HER kinase inhibition in patients with HER2- and HER3-mutant cancers |
| Q53691004 | HER2 genomic amplification in circulating tumor DNA and estrogen receptor positivity predict primary resistance to trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer. |
| Q37588232 | HER2-HER3 dimer quantification by FLIM-FRET predicts breast cancer metastatic relapse independently of HER2 IHC status |
| Q89446547 | HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis |
| Q38648765 | HER2-positive breast cancer is lost in translation: time for patient-centered research |
| Q64078065 | HER2-positive breast cancer: new therapeutic frontiers and overcoming resistance |
| Q41899812 | High PTEN gene expression is a negative prognostic marker in human primary breast cancers with preserved p53 function |
| Q26777681 | Human epidermal growth factor receptor 2 positive (HER2+) metastatic breast cancer: how the latest results are improving therapeutic options |
| Q38770018 | IGF1R Protein Expression Is Not Associated with Differential Benefit to Concurrent Trastuzumab in Early-Stage HER2+ Breast Cancer from the North Central Cancer Treatment Group (Alliance) Adjuvant Trastuzumab Trial N9831. |
| Q40282730 | Identification of E545k mutation in plasma from a PIK3CA wild-type metastatic breast cancer patient by array-based digital polymerase chain reaction: Circulating-free DNA a powerful tool for biomarker testing in advance disease |
| Q51663342 | Immunoglobulin G fragment C receptor polymorphisms and efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in HER2-positive breast cancer. |
| Q48173008 | Impact of serum HER2, TIMP-1, and CAIX on outcome for HER2+ metastatic breast cancer patients: CCTG MA.31 (lapatinib vs. trastuzumab). |
| Q90325432 | Is HER2-positive metastatic breast cancer still an incurable disease? |
| Q89592800 | MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2-Positive and/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 Trial |
| Q26752780 | Mechanisms Behind the Resistance to Trastuzumab in HER2-Amplified Breast Cancer and Strategies to Overcome It |
| Q26772969 | Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer |
| Q38901163 | Metastatic breast cancer: The Odyssey of personalization |
| Q37631514 | Molecular Biomarkers for Prediction of Targeted Therapy Response in Metastatic Breast Cancer: Trick or Treat? |
| Q91782988 | Molecular Decision Tree Algorithms Predict Individual Recurrence Pattern for Locally Advanced Nasopharyngeal Carcinoma |
| Q26751172 | Molecular Testing and the Pathologist's Role in Clinical Trials of Breast Cancer |
| Q51711213 | Molecular evaluation of PIK3CA gene mutation in breast cancer: determination of frequency, distribution pattern and its association with clinicopathological findings in Indian patients. |
| Q47782850 | Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+ primary breast cancer: A randomised, double-blind, placebo-controlled phase II trial (NeoPHOEBE). |
| Q55428234 | Neoadjuvant chemotherapy in breast cancer: a dose-dense schedule in real life and putative role of PIK3CA mutations. |
| Q38782016 | New insights on PI3K/AKT pathway alterations and clinical outcomes in breast cancer |
| Q38591976 | Non-HER2 signaling pathways activated in resistance to anti-HER2 therapy in breast cancer. |
| Q28066819 | Overview of the CLEOPATRA Trial: Implications for Advanced Practitioners |
| Q28081992 | PI3K mutations in breast cancer: prognostic and therapeutic implications |
| Q34776179 | PI3K/AKT/mTOR pathway activation in primary and corresponding metastatic breast tumors after adjuvant endocrine therapy |
| Q39023175 | PI3K/AKT/mTOR: role in breast cancer progression, drug resistance, and treatment |
| Q89529833 | PIK3CA H1047R Mutation Associated with a Lower Pathological Complete Response Rate in Triple-Negative Breast Cancer Patients Treated with Anthracycline-Taxane-Based Neoadjuvant Chemotherapy |
| Q64106572 | PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial |
| Q37380424 | PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer |
| Q39767744 | PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab. |
| Q54187441 | PIK3CA mutations in HER2-positive breast cancer: an ongoing conundrum. |
| Q28247338 | PIK3CA mutations in breast cancer: reconciling findings from preclinical and clinical data |
| Q33364587 | Pertuzumab and breast cancer: another piece in the anti-HER2 puzzle |
| Q39701009 | Pertuzumab and trastuzumab: the rationale way to synergy |
| Q36336483 | Pertuzumab for the treatment of patients with human epidermal growth factor receptor 2-positive breast cancer in Japan |
| Q38286163 | Pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer |
| Q91706604 | Pertuzumab in the treatment of HER2-positive breast cancer: an evidence-based review of its safety, efficacy, and place in therapy |
| Q55078620 | Pertuzumab, trastuzumab and eribulin mesylate therapy for previously treated advanced HER2-positive breast cancer: a feasibility study with analysis of biomarkers. |
| Q90325424 | Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study |
| Q27853134 | Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer |
| Q38573858 | Pharmacokinetics, pharmacodynamics and clinical efficacy of pertuzumab in breast cancer therapy |
| Q36963374 | Phase I Study of an AKT Inhibitor (MK-2206) Combined with Lapatinib in Adult Solid Tumors Followed by Dose Expansion in Advanced HER2+ Breast Cancer |
| Q47938353 | Phase II study of buparlisib (BKM120) and trastuzumab in patients with HER2+ locally advanced or metastatic breast cancer resistant to trastuzumab-based therapy |
| Q57494109 | Plasma PIK3CA ctDNA specific mutation detected by next generation sequencing is associated with clinical outcome in advanced breast cancer |
| Q90393366 | Precision Genomic Practice in Oncology: Pharmacist Role and Experience in an Ambulatory Care Clinic |
| Q38551394 | Precision medicine for metastatic breast cancer--limitations and solutions. |
| Q52655751 | Prevalence and Prognostic Role of PIK3CA/AKT1 Mutations in Chinese Breast Cancer Patients. |
| Q49478004 | Profile of buparlisib and its potential in the treatment of breast cancer: evidence to date |
| Q90226704 | Prognostic and Predictive Implications of PTEN in Breast Cancer: Unfulfilled Promises but Intriguing Perspectives |
| Q36064908 | Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast Cancer |
| Q41037554 | Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer |
| Q92413714 | Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer |
| Q39591068 | Relationship between tumor biomarkers and efficacy in TH3RESA, a phase III study of trastuzumab emtansine (T-DM1) vs. treatment of physician's choice in previously treated HER2-positive advanced breast cancer |
| Q90664778 | Review ctDNA and Breast Cancer |
| Q39886748 | Ridaforolimus improves the anti-tumor activity of dual HER2 blockade in uterine serous carcinoma in vivo models with HER2 gene amplification and PIK3CA mutation |
| Q36069770 | Serum HER2 extra-cellular domain, S100ß and CA 15-3 levels are independent prognostic factors in metastatic breast cancer patients |
| Q92474309 | Stromal Tumor-infiltrating Lymphocytes in NRG Oncology/NSABP B-31 Adjuvant Trial for Early-Stage HER2-Positive Breast Cancer |
| Q52664052 | Study on the progression types of cancer in patients with breast cancer undergoing eribulin chemotherapy and tumor microenvironment. |
| Q26830496 | Targeted therapy for HER2 positive breast cancer |
| Q35239603 | Targeted therapy in her2-positive metastatic breast cancer: a review of the literature |
| Q38632768 | Targeting HER2 in Advanced Breast Cancer |
| Q39441303 | Targeting PI3K Signaling in Combination Cancer Therapy. |
| Q64064458 | Targeting promiscuous heterodimerization overcomes innate resistance to ERBB2 dimerization inhibitors in breast cancer |
| Q46087491 | Targeting protein quality control pathways in breast cancer |
| Q55216913 | The Conundrum of Adjuvant HER2 Treatment Options. |
| Q36064912 | The Therapeutic Challenge of Targeting HER2 in Endometrial Cancer |
| Q39312902 | The Therapeutic Potential of PI3K/Akt/mTOR Inhibitors in Breast Cancer: Rational and Progress |
| Q36761689 | The clinical value of HER-2 overexpression and PIK3CA mutations in the older breast cancer population: a FOCUS study analysis. |
| Q37327307 | The combination of trastuzumab and pertuzumab administered at approved doses may delay development of trastuzumab resistance by additively enhancing antibody-dependent cell-mediated cytotoxicity |
| Q35653163 | The expanding role of pertuzumab in the treatment of HER2-positive breast cancer |
| Q41645967 | The predictive and prognostic role of phosphatase phosphoinositol-3 (PI3) kinase (PIK3CA) mutation in HER2-positive breast cancer receiving HER2-targeted therapy: a meta-analysis |
| Q61805844 | The prognostic value of the Tau protein serum level in metastatic breast cancer patients and its correlation with brain metastases |
| Q64256540 | The role of the phosphatase and tensin homolog status in predicting pathological complete response to neoadjuvant anti-HER2 therapies in HER2-positive primary breast cancer: A meta-analysis |
| Q39257898 | Transcriptome- and proteome-oriented identification of dysregulated eIF4G, STAT3, and Hippo pathways altered by PIK3CA H1047R in HER2/ER-positive breast cancer |
| Q89727324 | Trastuzumab Emtansine: Mechanisms of Action and Resistance, Clinical Progress, and Beyond |
| Q88110927 | Trastuzumab emtansine in HER2-positive metastatic breast cancer |
| Q91986598 | Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2-positive advanced breast cancer: Final results from MARIANNE |
| Q35740877 | Treatment of HER2-positive breast cancer. |
| Q35085679 | Trogocytosis-mediated expression of HER2 on immune cells may be associated with a pathological complete response to trastuzumab-based primary systemic therapy in HER2-overexpressing breast cancer patients |
| Q38376822 | Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study |
| Q52609428 | Use of the tumor-infiltrating CD8 to FOXP3 lymphocyte ratio in predicting treatment responses to combination therapy with pertuzumab, trastuzumab, and docetaxel for advanced HER2-positive breast cancer. |
Search more.